Catdesivir is finally getting a chance in Covid-19
A close molecular cousin to Gilead Sciences’ remdesivir, which has long been used to treat a different coronavirus in cats, will soon be tested as a treatment for Covid-19, following months of advocacy from independent scientists.
As STAT’s Ed Silverman reports, researchers at the NIH are moving forward with GS-441524, an antiviral compound that, in lab tests, appears to replicate remdesivir’s effects on Covid-19 with less toxicity. The drug is also easier to synthesize, which might make it a viable oral treatment. Remdesivir is administered intravenously.
Whether GS-441524 pans out remains to be seen, but the NIH’s decision is a victory for the MD Anderson Cancer Center, which had been pressuring Gilead to advance the compound into clinical trials.
Read more.
As STAT’s Ed Silverman reports, researchers at the NIH are moving forward with GS-441524, an antiviral compound that, in lab tests, appears to replicate remdesivir’s effects on Covid-19 with less toxicity. The drug is also easier to synthesize, which might make it a viable oral treatment. Remdesivir is administered intravenously.
Whether GS-441524 pans out remains to be seen, but the NIH’s decision is a victory for the MD Anderson Cancer Center, which had been pressuring Gilead to advance the compound into clinical trials.
Read more.
.png)
No hay comentarios:
Publicar un comentario